Advicenne SA
PAR:ALDVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (6.5), the stock would be worth €-1.06 (182% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8 | €1.3 |
0%
|
| Industry Average | 6.5 | €-1.06 |
-182%
|
| Country Average | 13.2 | €-2.16 |
-266%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€47.3m
|
/ |
Jul 2025
€-4.6m
|
= |
|
|
€47.3m
|
/ |
Dec 2025
€-6.1m
|
= |
|
|
€47.3m
|
/ |
Dec 2026
€-2.8m
|
= |
|
|
€47.3m
|
/ |
Dec 2027
€927k
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Advicenne SA
PAR:ALDVI
|
18.9m EUR | -8 | -3.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 30.3 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 21.6 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 22.7 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 11.8 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.3 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 10 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.5 |
| Median | 13.2 |
| 70th Percentile | 17.5 |
| Max | 1 862.3 |
Other Multiples
Advicenne SA
Glance View
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Nimes, Occitanie and currently employs 30 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
